ROYAL BANK OF CANADA - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 237 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2023. The put-call ratio across all filers is 1.12 and the average weighting 0.2%.

Quarter-by-quarter ownership
ROYAL BANK OF CANADA ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q2 2024$191,000
-39.7%
4,678
-31.2%
0.00%
Q1 2024$317,000
-80.1%
6,798
-79.6%
0.00%
Q4 2023$1,590,000
+24.9%
33,247
-7.0%
0.00%
Q3 2023$1,273,000
-51.4%
35,749
-37.0%
0.00%
-100.0%
Q2 2023$2,618,000
+15.0%
56,735
-0.1%
0.00%0.0%
Q1 2023$2,277,000
+1055.8%
56,778
+1236.0%
0.00%
Q4 2022$197,000
+27.1%
4,250
+13.0%
0.00%
Q3 2022$155,000
-62.2%
3,760
-45.1%
0.00%
Q2 2022$410,000
-22.1%
6,852
-5.5%
0.00%
Q1 2022$526,000
-28.3%
7,251
-16.9%
0.00%
Q4 2021$734,000
+2.1%
8,727
+9.3%
0.00%
Q3 2021$719,000
-76.4%
7,988
-75.0%
0.00%
-100.0%
Q2 2021$3,052,000
+319.8%
32,006
+401.7%
0.00%
Q1 2021$727,000
+6.0%
6,379
+28.6%
0.00%
Q4 2020$686,000
+253.6%
4,961
+109.8%
0.00%
Q3 2020$194,000
+104.2%
2,365
+95.6%
0.00%
Q2 2020$95,000
+1087.5%
1,209
+598.8%
0.00%
Q1 2020$8,000
-92.5%
173
-93.2%
0.00%
Q4 2019$107,000
+64.6%
2,531
+64.5%
0.00%
Q3 2019$65,000
+441.7%
1,539
+650.7%
0.00%
Q2 2019$12,000
-85.9%
205
-83.2%
0.00%
Q1 2019$85,000
+102.4%
1,223
+28.1%
0.00%
Q4 2018$42,000
-75.6%
955
-57.6%
0.00%
Q3 2018$172,000
+11.0%
2,255
+11.4%
0.00%
Q2 2018$155,000
+868.8%
2,025
+526.9%
0.00%
Q1 2018$16,000
-99.9%
323
-99.9%
0.00%
-100.0%
Q4 2017$12,608,000
+2.9%
271,845
+18.1%
0.01%0.0%
Q3 2017$12,253,000
-12.0%
230,087
+2.6%
0.01%
-14.3%
Q2 2017$13,929,000
+846.9%
224,261
+933.2%
0.01%
+600.0%
Q1 2017$1,471,000
-86.5%
21,705
-86.0%
0.00%
-83.3%
Q4 2016$10,885,000
-6.7%
154,804
-5.9%
0.01%0.0%
Q3 2016$11,672,000
+78.9%
164,538
+23.3%
0.01%
+50.0%
Q2 2016$6,526,000
-10.7%
133,424
+15.5%
0.00%
-20.0%
Q1 2016$7,311,000
+182675.0%
115,483
+360784.4%
0.01%
Q4 2015$4,000
-97.7%
32
-98.2%
0.00%
Q3 2015$173,000
-59.8%
1,798
-57.2%
0.00%
Q2 2015$430,000
-38.7%
4,200
-62.8%
0.00%
Q1 2015$702,00011,3000.00%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q4 2023
NameSharesValueWeighting ↓
First Light Asset Management, LLC 217,459$24,760,0001.64%
Motley Fool Asset Management LLC 152,326$17,344,0001.25%
Rock Springs Capital Management LP 450,000$51,237,0001.12%
AtonRa Partners 21,017$2,393,0001.07%
SECTORAL ASSET MANAGEMENT INC 112,200$12,775,0000.97%
EMERALD ADVISERS, LLC 228,368$26,002,0000.94%
EMERALD MUTUAL FUND ADVISERS TRUST 239,023$27,215,0000.90%
FEDERATED HERMES, INC. 3,912,408$445,467,0000.86%
HealthCor Management, L.P. 207,610$23,638,0000.84%
Atika Capital Management LLC 66,000$7,515,0000.65%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders